Our News
Prof. Peixuan Guo as the Founder of ExonanoRNA LLC is Elected as the Fellow Member of the National Academy of Inventors
On December 8, 2022, Dr. Peixuan Guo, pioneer of RNA nanotechnology, discoverer of revolution motor, Sylvan G. Frank Endowed Chair Professor in Pharmaceutics and Drug Delivery in the College of Pharmacy at The Ohio State University is elected as a member of the National Academy of Inventors...
ExonanoRNA Founder Receives the Ohio State University, 2021 Innovator of the Year Award
The prestigious award recognizes research, innovation, and entrepreneurial leadership Columbus, OH – April 15, 2021ExonanoRNA, LLC, today announced that Dr. Peixuan Guo, Chairman and Founder, has received the prestigious Innovator of the Year Award 2021 from the Ohio State University. This award...
ExonanoRNA and MDimune Enter Service Agreement to Advance Targeted Delivery for Cancer
ExonanoRNA LLC., based in Columbus, Ohio, and MDimune Inc., headquartered in Seoul, South Korea, have entered into a service agreement to develop targeted siRNA therapy in oncology application on October 8th, 2021. By combining ExonanoRNA’s RNA NanoParticle Displaying Exosomes Delivery System...
ExonanoRNA is Officially Approved as University Technology Commercialization Company
ExonanoRNA becomes Ohio State University UTCC Company
ExonanoRNA Wins 2020 M2D2 $200K Challenge
Columbus, OH – ExonanoRNA is proud to announce it has been selected as a winner for the University of Massachusetts’ 2020 M2D2 $200k Challenge, receiving an Industry Partner Award from Sarepta Therapeutics. The M2D2 $200k Challenge aims to provide support to new and emerging biotech and medical...
RNA Nanoparticles as Rubber to Enhance Tumor Targeting
We are excited to share a new publication from Dr. Peixuan Guo’s lab elucidating the elastic and rubbery properties of RNA nanoparticles.
RNA Nanotechnology for Improved Cancer Treatments
Columbus, Ohio – A new breakthrough study was published in Nature Communications recently. This study was led by our president, Dr. Peixuan Guo, in addition to our VP, Mario Vieweger, as a co-author. Paclitaxel is a very common chemotherapeutic drug, but due to its poor water-solubility and...
ExonanoRNA is Taking Action to Defeat the 2019 Novel Coronavirus (2019-nCoV)
ExonanoRNA is donating research reagents to qualified individuals or organizations developing new medical treatments for the novel coronavirus. This new coronavirus is a member of a family of RNA viruses, and the typical genome for a generic coronavirus is a single strand of RNA with 32 kilobases....
Insightscare Names ExonanoRNA One of the Most Innovative Healthcare Nanotech Companies to Watch in 2019
ExonanoRNA is pleased to announce that it has been named one of the “10 Most Innovative Healthcare Nanotech Companies to Watch” by Insights Care Magazine. This article outlines our company’s mission and history.
ExonanoRNA Offers New Promotion for Christmas
We want to wish you a merry Christmas this year by providing a special 15% discount code, Merry2019, for our products and services until December 31, 2019. Among our featured products are:
1. Custom Oligo synthesis (RNA, 2’F-RNA, 2’-OMethyl RNA, LNA and others, 0.2-60 μmole synthesis scale)…
